Bel Air Pharmaceuticals

CA - Beverly HillsDiagnostics1 H-1B visas (FY2023)

Focus: Bel Air Pharmaceuticals is a newly founded (2024) specialty pharma company headquartered in Beverly Hills focused on diagnostics, wound care, and pain management with a neurology therapeutic area. The company operates a portfolio of legacy branded and generic medications with significant revenue concentration in a single product.

Neurology

Profile data last refreshed 43m ago · AI intelligence enriched 2w ago

Open Jobs

About Bel Air Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Bel Air Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

1 in 5yr

ONMEL

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TOLSURA

HIV Infection, Histoplasmosis, Blastomycosis

$0.769M Part D

Peak7.1yr

Help build intelligence for Bel Air Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TOLSURA (itraconazole) at peak lifecycle with LOE protection until 2033 provides stable revenue foundation and job security
Newly founded company (2024) creates opportunity to shape culture, processes, and strategic direction from the ground up
Portfolio includes multiple marketed NDAs across high-demand therapeutic areas (antifungal, hypertension, depression) with established market presence

Watch Out For

Zero active clinical development pipeline (0 Phase 1/2/3 trials) signals minimal R&D investment and limited growth catalyst visibility
60% revenue concentration in single product creates acute vulnerability; PEXEVA and TRANDATE approaching LOE with no disclosed pipeline replacements
Extremely early-stage company with no disclosed funding, employee count, or financial data raises transparency and stability concerns

Generated by Claude from Bel Air Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Anchor product generating 60% of company revenue with 9-year patent protection; primary job security driver.

PEXEVA

Hot Flashes, Postmenopausal Symptoms

$0.508M Part D

LOE Approaching

Second-largest revenue contributor facing imminent loss of exclusivity with no disclosed mitigation strategy.

TRANDATE

Severe Hypertension

LOE Approaching

Legacy hypertension product nearing exclusivity cliff with minimal disclosed Part D spending.

ONMEL

Antifungal Prophylaxis, Invasive Fungal Infections, Non-Small Cell Lung Cancer